Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension

NCT02235909 is registered in ClinicalTrials.gov with Arbor Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02235909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02235909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Efficacy and Safety Study of AR 14 (AZILSARTAN MEDOXOMIL) Treatment and Withdrawal, Followed by an Open-Label Extension, in Children 6 to Less Than 18 Years of Age With Hypertension
Lead sponsor
Arbor Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 30, 2015
Completion date
November 11, 2019
Enrollment
377 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension